1. Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095–2128 (2012).
2. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 349, 1569–1581 (1997).
3. National Institute of Neurological, D. & Stroke rt, P.A.S.S.G. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333, 1581–1587 (1995).
4. Berkhemer, O. A. et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 372, 11–20 (2015).
5. Powers, W. J. et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 49, e46–e110 (2018).
6. Chamorro, A., Dirnagl, U., Urra, X. & Planas, A. M. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol 15, 869–881 (2016).
7. Ikeda, H. O. et al. Novel VCP modulators mitigate major pathologies of rd10, a mouse model of retinitis pigmentosa. Sci Rep 4, 5970 (2014).
8. Meyer, H., Bug, M. & Bremer, S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat Cell Biol 14, 117–123 (2012).
9. Nakano, N. et al. Neuroprotective effects of VCP modulators in mouse models of glaucoma. Heliyon 2, e00096 (2016).
10. Hasegawa, T. et al. Neuoroprotective efficacies by KUS121, a VCP modulator, on animal models of retinal degeneration. Sci Rep 6, 31184 (2016).
11. Hata, M. et al. KUS121, a VCP modulator, attenuates ischemic retinal cell death via suppressing endoplasmic reticulum stress. Sci Rep 7, 44873 (2017).
12. Nakano, M. et al. ATP Maintenance via Two Types of ATP Regulators Mitigates Pathological Phenotypes in Mouse Models of Parkinson’s Disease. EBioMedicine 22, 225–241 (2017).
13. Tasca, C. I., Dal-Cim, T. & Cimarosti, H. In vitro oxygen-glucose deprivation to study ischemic cell death. Methods Mol Biol 1254, 197–210 (2015).
14. Kasahara, Y. et al. A highly reproducible model of cerebral ischemia/reperfusion with extended survival in CB-17 mice. Neurosci Res 76, 163–168 (2013).
15. Doyle, K. P., Fathali, N., Siddiqui, M. R. & Buckwalter, M. S. Distal hypoxic stroke: a new mouse model of stroke with high throughput, low variability and a quantifiable functional deficit. J Neurosci Methods 207, 31–40 (2012).
16. Tajiri, S. et al. Ischemia-induced neuronal cell death is mediated by the endoplasmic reticulum stress pathway involving CHOP. Cell Death Differ 11, 403–415 (2004).
17. Ding, W. X. et al. Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. J Biol Chem 282, 4702–4710 (2007).
18. Marciniak, S. J. et al. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev 18, 3066–3077 (2004).
19. Oyadomari, S. & Mori, M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 11, 381–389 (2004).
20. Xing, C., Arai, K., Lo, E. H. & Hommel, M. Pathophysiologic cascades in ischemic stroke. Int J Stroke 7, 378–385 (2012).
21. Moskowitz, M. A., Lo, E. H. & Iadecola, C. The science of stroke: mechanisms in search of treatments. Neuron 67, 181–198 (2010).
22. Kalogeris, T., Baines, C. P., Krenz, M. & Korthuis, R. J. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 298, 229–317 (2012).
23. Tymianski, M., Charlton, M. P., Carlen, P. L. & Tator, C. H. Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons. J Neurosci 13, 2085–2104 (1993).
24. Sattler, R. & Tymianski, M. Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol Neurobiol 24, 107–129 (2001).
25. Luo, Y. et al. Recent advances in the development of neuroprotective agents and therapeutic targets in the treatment of cerebral ischemia. Eur J Med Chem 162, 132–146 (2019).
26. MacDermott, A. B., Mayer, M. L., Westbrook, G. L., Smith, S. J. & Barker, J. L. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature 321, 519–522 (1986).
27. Yu, G., Wu, F. & Wang, E. S. BQ-869, a novel NMDA receptor antagonist, protects against excitotoxicity and attenuates cerebral ischemic injury in stroke. Int J Clin Exp Pathol 8, 1213–1225 (2015).
28. Warner, D. S., Sheng, H. & Batinic-Haberle, I. Oxidants, antioxidants and the ischemic brain. J Exp Biol 207, 3221–3231 (2004).
29. Mizuma, A. & Yenari, M. A. Anti-Inflammatory Targets for the Treatment of Reperfusion Injury in Stroke. Front Neurol 8, 467 (2017).
30. Rutkowski, D. T. et al. Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biol 4, e374 (2006).
31. Nies, A. T. et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 129, 349–360 (2004).
32. Cammer, W., Downing, M., Clarke, W. & Schenkman, J. B. Immunocytochemical staining of the RLM6 form of cytochrome P-450 in oligodendrocytes and myelin of rat brain. J Histochem Cytochem 39, 1089–1094 (1991).
33. Ravindranath, V. et al. Xenobiotic metabolism in brain. Toxicol Lett 82–83, 633–638 (1995).
34. Melani, A. et al. ATP extracellular concentrations are increased in the rat striatum during in vivo ischemia. Neurochem Int 47, 442–448 (2005).
35. Cavaliere, F. et al. Glucose deprivation and chemical hypoxia: neuroprotection by P2 receptor antagonists. Neurochem Int 38, 189–197 (2001).
36. Amadio, S. et al. P2 receptor modulation and cytotoxic function in cultured CNS neurons. Neuropharmacology 42, 489–501 (2002).
37. Maki, T. et al. Adrenomedullin promotes differentiation of oligodendrocyte precursor cells into myelin-basic-protein expressing oligodendrocytes under pathological conditions in vitro. Stem Cell Res 15, 68–74 (2015).
38. Maki, T. et al. Phosphodiesterase III inhibitor promotes drainage of cerebrovascular beta-amyloid. Ann Clin Transl Neurol 1, 519–533 (2014).